Table 3:
Results of FDA-approved diagnostic assays a in nine discordant samples from seroconverters (SC) with G4 LAB-plasma Reactive and POC-blood Nonreactive results
| Days after first sample collected: | RNA: | Ag/Ab: | IgG/IgM: | IgG Suppl: | |||
|---|---|---|---|---|---|---|---|
| SC#: | APT-Qual | Architect | Determine | GS+O | Geenius | ||
| Ag | Ab | ||||||
| 9 | 10 | Pos | R | NR | R | R | HIV-1 Pos |
| 7 | 11 | Pos | R | R | NR | R | HIV Neg |
| 11 | 29 | Pos | R | NR | R | NR | HIV Neg |
| 10 | 35 | Pos | R | R | NR | R | HIV Neg |
| 4 | 44 | Pos | R | R | R | R | HIV-1 Ind |
| 14 | 57 | Pos | R | NR | R | R | HIV-1 Pos |
| 14 | 71b | Pos | R | NR | R | R | HIV-1 Pos |
| 15 | 49 | Pos | R | R | NR | R | HIV Neg |
| 15 | 64b | Pos | R | NR | R | R | HIV-1 Pos |
a
Plasma testing: HIV-1 RNA assay: Aptima HIV-1 Qualitative Assay (APT-Qual), Ag/Ab assays: Architect HIV Ag/Ab Combo Assay, Determine HIV-1/2 Ag/Ab Combo, IgG/IgM assay: GS HIV-1/HIV-2 PLUS O EIA (GS+O), IgG supplemental assay (IgG Suppl.): Geenius HIV-1/2 Assay.
b
Samples that became nonreactive in blood after a first POC-reactive test result, potentially due to a second negative diagnostic phase during seroconversion. Sample from SC#14 became nonreactive 12 days after first POC-reactive result, and SC#15 became nonreactive 2 days after first POC-reactive result.